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Background: The population is aging and multimorbidity is becoming a common problem 
in the elderly.
Objective: To explore the effect of multimorbidity patterns on mortality for all causes at 3- and 
5-year follow-up periods.
Materials and methods: A prospective community-based cohort (2009–2014) embedded 
within a randomized clinical trial was conducted in seven primary health care centers, including 
328 subjects aged 85 years at baseline. Sociodemographic variables, sensory status, cardiovascular 
risk factors, comorbidity, and geriatric tests were analyzed. Multimorbidity patterns were defined 
as combinations of two or three of 16 specific chronic conditions in the same individual.
Results: Of the total sample, the median and interquartile range value of conditions was 4 
(3–5). The individual morbidities significantly associated with death were chronic obstructive 
pulmonary disease (COPD; hazard ratio [HR]: 2.47; 95% confidence interval [CI]: 1.3; 4.7), 
atrial fibrillation (AF; HR: 2.41; 95% CI: 1.3; 4.3), and malignancy (HR: 1.9; 95% CI: 1.0; 
3.6) at 3-year follow-up; whereas dementia (HR: 2.04; 95% CI: 1.3; 3.2), malignancy (HR: 
1.84; 95% CI: 1.2; 2.8), and COPD (HR: 1.77; 95% CI: 1.1; 2.8) were the most associated 
with mortality at 5-year follow-up, after adjusting using Barthel functional index (BI). The 
two multimorbidity patterns most associated with death were AF, chronic kidney disease 
(CKD), and visual impairment (HR: 4.19; 95% CI: 2.2; 8.2) at 3-year follow-up as well as 
hypertension, CKD, and malignancy (HR: 3.24; 95% CI: 1.8; 5.8) at 5 years, after adjust-
ing using BI.
Conclusion: Multimorbidity as specific combinations of chronic conditions showed an effect 
on mortality, which would be higher than the risk attributable to individual morbidities. The 
most important predicting pattern for mortality was the combination of AF, CKD, and visual 
impairment after 3 years. These findings suggest that a new approach is required to target 
multimorbidity in octogenarians.
Keywords: oldest old, multimorbidity, chronic diseases, mortality, atrial fibrillation, malignancy
Introduction
Multimorbidity is highly prevalent in the elderly, and such coexistence leads to 
long-term disorders.1 However, health care systems are largely aimed at individual 
diseases rather than multimorbidity often redundant, impractical, and sometimes even 
harmful care.2,3 The prevalence of multimorbidity is reported to be 62% among those 
aged 65–74 years and 82% for those aged $85 years.4 Therefore, medical research is 
needed to assess a more comprehensive clinical approach to multimorbidity and its 
effects, particularly in the oldest old.5–7
Correspondence: Assumpta Ferrer
CAP – El Plà: Pl, Felip Alcantara 
s/n 08980, Sant Feliu de Llobregat, 
Barcelona, Spain
Tel +34 936 85 2888
Fax +34 932 60 7420
email aferrer.cp.ics@gencat.cat
Journal name: Clinical Interventions in Aging
Article Designation: Original Research
Year: 2017
Volume: 12
Running head verso: Ferrer et al
Running head recto: Multimorbidity patterns and survival in elderly
DOI: http://dx.doi.org/10.2147/CIA.S123173
 
Cl
in
ica
l I
nt
er
ve
nt
io
ns
 in
 A
gi
ng
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
83
.5
5.
21
8.
47
 o
n 
17
-F
eb
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical Interventions in Aging 2017:12submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
224
Ferrer et al
The evaluation of multimorbidity is difficult; thus, 
consensus regarding the number and types of diseases that 
should be included in multimorbidity does not exist,8 and 
prevalence estimates are highest when using an open list of 
diagnoses, data from general practice (eg, general population 
or patients from general practice), and a low cutoff point 
conditions (eg, if multimorbidity is defined by a minimum 
of two or three diagnoses).4,8 Conversely, the effects of 
multimorbidity remain uncertain, specifically those related 
to mortality. In previous studies, beyond a reported effect on 
mortality at 10 years and 3 years of multimorbidity in young 
elders9,10 and in octogenarians,11,12 multimorbidity lost its 
effect when adjusted for functionality. Recent research has 
begun to focus on more comprehensive perspective rather 
than the concept of multimorbidity as a summary of indices, 
in order to understand how morbidities cluster or co-occur 
in the same individual.13,14 This would be important because 
the concept of multimorbidity as specific disease-to-disease 
interactions within combinations may accelerate the develop-
ment of functional limitations, disability, and mortality.5,10
In light of the above, the aim of this study was to explore 
the association between the patterns of multimorbidity by 
specific group diseases and survival after 3 and 5 years of 
follow-up periods, in an existing population-based cohort 
study of aging and falling of octogenarians.
Materials and methods
The current data were gathered from the longitudinal data 
set of Octabaix study project, a 3-year randomized clinical 
intervention program to prevent falls and malnutrition in 328 
community-dwelling inhabitants all born in the year 1924.15,16 
The Octabaix project is a prospective population-based study 
on aging with a primary purpose on falls and malnutrition 
assessment. All community-dwelling inhabitants born in 
1924 (aged 85 years at the time of inclusion) and registered 
at one of seven primary health care centers in Baix Llobregat 
in Barcelona, Spain, were contacted. The combined popula-
tion served by these health care teams included ~210,000 
inhabitants of the nearly 800,000 inhabitants in the whole of 
the Baix Llobregat area. The corresponding referral hospital, 
at the time the study began, was the Hospital Universitari 
de Bellvitge. Geriatric assessment was performed, and 
sociodemographic data were recorded. The study included, 
from among 487 eligible subjects, 328 noninstitutionalized 
participants. No criteria related to baseline health or cognitive 
status was applied to exclude patients. The only exclusion 
criterion was to be institutionalized. Different reasons for 
noninclusion were 76 (10.9%) living in unregistered nursing 
homes as listed, 67 (9.6%) died before the study started, and 
66 (9.4%) displaced to another city. The participation rate 
was 67.5%, and there were no differences among respondents 
and nonrespondents in terms of gender, health care center, 
or physician in charge. The study was approved by the 
institutional ethics committee of the Jordi Gol Institute for 
Primary Care Research IDIAP. All patients or their caregivers 
gave written informed consent before enrollment.
Subjects were examined by medical doctors and nurses, 
specially trained in elderly interviewing to control the inter-
rater reliability. The interview was done at the place of resi-
dence of participants and included a geriatric assessment and 
the collection of sociodemographic data. Functional status 
was measured using the Barthel functional index (BI)17 for 
the basic activities of daily living (ADL). The total score 
of the BI ranges from 0 to 100 points (from help needed 
to be independent in all activities). Cognitive function was 
measured by the Spanish version of the Mini-Mental State 
Examination (MEC)18 (lower or equal scoring to 23/35 
indicates cognitive impairment). The Charlson Index was 
used to measure global comorbidity.19 The Charlson score 
ranges from 0 to a theoretical maximum of 33, depending on 
the presence of certain diseases with assigned values. The 
Charlson Comorbidity Index was used to measure overall 
comorbidity. Scores here range from 0 to a theoretical maxi-
mum of 33, depending on the presence of certain diseases 
with assigned values. Nutritional status was assessed using 
the Mini-Nutritional Assessment,20 which has a maximum 
score of 30 and scores of ,23.5 classified as a risk of malnu-
trition. The clinical trial is registered in US National Institutes 
of Health Clinical Trial: NCT01141166.
Procedure
Multimorbidity was defined as the combination of 
co-occurred specific chronic conditions within one person. 
A disease was classified as chronic if it was permanent and 
caused by nonreversible pathological alterations. All data 
sources were coded according to the standardized ICD-10. 
For the purpose of this study, the analysis focused on the 
16 most common chronic health conditions:16 hypertension, 
diabetes mellitus, dyslipidemia, ischemic cardiomyopathy 
(including myocardial infarction, coronary heart disease, 
and angina), heart failure, stroke (including transient isch-
emic attack), chronic obstructive pulmonary disease (COPD 
(including chronic bronchitis or emphysema and asthma), 
atrial fibrillation (AF), peripheral arterial disease, Parkinson’s 
disease, malignancy (including any malignant tumors), 
dementia, anemia, chronic kidney disease (CKD when the 
glomerular filtration rate was ,60 mL/min/1.73 m2), visual 
impairment, and deafness.
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Mortality, measured as time to all-cause death, was 
considered the primary outcome. The vital status of the par-
ticipants was evaluated annually during the 5-year follow-up. 
Additionally for that purpose, we collected the exact date of 
death by other electronic clinical registers and if these dates 
were not available, then by death certificates. Participants who 
were unavailable for follow-up were censored at the time of 
dropping out and were included as censored information in 
the analysis.
Categorical variables are shown as frequencies and percent-
ages while quantitative variables are presented as median and 
interquartile range due to the nonnormality distribution of the 
variable (previously assessed by normal probability plots). In 
the bivariate analysis for baseline characteristics, either the chi-
square or Fisher’s exact test was used to compare categorical 
variables between men and women. The Mann–Whitney test 
was applied to compare quantitative variables across groups. 
A first analysis was performed by Kaplan–Meier curves for 
time to death at the 3- and 5-year follow-up periods for all 
individual 16 morbidities previously described. The three 
individual morbidities most associated with death on the high-
est chi-square from the log-rank test statistic were retained. 
A similar approach by Kaplan–Meier curves was used for all 
combinations of two and three morbidities. In these cases, for 
each of the possible combinations of two and three morbidities, 
participants of these particular combinations were compared 
to the rest (eg, in the scenario of two morbidities, participants 
with both A and B morbidities are compared to the rest includ-
ing those with none or at most one of two; the same reasoning 
is applied for three morbidities). On the basis of the chi-square 
log-rank test statistic performed for each combination, the 
three morbidities most associated for each group of variables 
were retained. A second analysis by Cox proportional hazard 
models was fit for the retained individual morbidity and combi-
nations of co-occurred morbidities. Models adjusted by gender 
and BI were also fit, and hazard ratios (HRs) with the 95% 
confidence interval (CI) were estimated. Proportional hazard 
assumptions were tested in all models performing scaled Schoe-
nfeld residuals and log (-log) transformation in Kaplan–Meier 
curves. Finally, for the two combined morbidity models retained, 
the interaction was tested assuming an alpha level of 0.05. All 
analyses were performed using R software (version 3.3.2; The 
R Foundation for Statistical Computing, Vienna, Austria).
Results
The sample included 202 women (61.6%) and 174 were 
widowed (53.0%). Sixty two (19.0%) had more than 6 years 
of formal education, while the remaining 266 (81.0%) 
had only primary schooling or no formal education at all. 
One hundred and seventy-four (53.0%) participants had a 
caregiver. In terms of functional status, the mean (standard 
deviation [SD]) BI score was 87.5 (19), whereas the mean of 
the MEC cognition test was 26.6 (6.8). Of the total sample, 
95.1% participants had more than one co-occurring disease 
of all the selected chronic conditions defined and the median 
and the interquartile range value of the number of chronic 
conditions was 4 (3–5) during the study period. Table 1 shows 
differences in baseline characteristics according to gender. 
Differences of gender in these morbidities were a greater 
number of COPD (P=0.016), malignancy (P,0.001), and 
nutritional risk (P=0.016) in men; whereas, women had more 
cognitive decline (P=0.040) and falls (P=0.006).
Of the total sample, 59 (18.0%) subjects died by the third 
year and 146 (44.5%) by the fifth year. Figure 1 shows the 
individual morbidities and multimorbidity combinations 
most associated, with time to death at 3- and 5-year follow-up 
periods, respectively. Tables 2 and 3 show the individual 
morbidities and disease combinations most associated with 
time to death. The individual morbidities significantly associ-
ated with death were COPD (HR: 2.47; 95% CI: 1.3; 4.7), AF 
(HR: 2.41; 95% CI: 1.3; 4.3), and malignancy (HR: 1.9; 95% 
CI: 1.0; 3.6) by 3 years, whereas dementia (HR: 2.04; 95% 
CI: 1.3; 3.2), malignancy (HR: 1.84; 95% CI: 1.2; 2.8), and 
COPD (HR: 1.77; 95% CI: 1.1; 2.8) were the most associ-
ated with mortality at 5-year follow-up, after adjustment 
through BI. During the 3-year follow-up period, patterns of 
multimorbidity groups for two diseases showed an HR of 
mortality of 3.81 (1.9; 7.4) for AF and CKD, 2.66 (1.5; 4.8) 
for AF and visual impairment, and 2.40 (1.2; 4.9) for anemia 
and CKD adjusting by BI. For the group of three diseases, 
AF, CKD, and visual impairment with an HR of 4.19 (2.2; 
8.2) was the most important multimorbidity associated with 
death (in the BI adjusted model). At the 5-year follow-up 
period, patterns of multimorbidity for two and three diseases 
showed a significant HR of death of 2.66 (1.4; 5.0) for anemia 
and malignancy, 3.24 (1.8; 5.8) for hypertension, CKD, and 
malignancy, and 2.91 (1.7; 5.0) for dyslipidemia, malignancy, 
and visual impairment, after adjustment through BI.
Table 4 shows that for the 5-year follow-up period, the 
most significant interaction was found between dyslipidemia 
and malignancy (P=0.005). In the other models, no statistical 
interactions were found. For the 3-year follow-up period, 
no interaction between either the two retained comorbidity 
models was found.
Discussion
This study found that multimorbidity patterns of AF, 
CKD, and visual impairment at 3-year follow-up, whereas 
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hypertension, CKD, and malignancy at 5-year follow-up are 
the most important predicting factors for mortality. When 
cancer co-occurred with other conditions, it appeared as an 
important synergistic factor that intensified mortality risk. 
Therefore, multimorbidity may lead specific disease com-
binations to have more than an additive risk on the effect 
of death.
Several studies have demonstrated the effect of mul-
timorbidity on mortality, such as the Lee et al study21 on 
population-based community-dwelling adults in the USA 
and Walter et al22 on hospitalized patients. However, dif-
ferences between studies existed and methods varied. 
Therefore, besides the reported influence of the number 
of diseases included in the definition of multimorbidity, 
which directly increases the risk of mortality,23 a second 
reason for these differences may be the choice of the condi-
tions included in multimorbidity indices. These conditions 
should preferably be related to the (primary) study outcome 
because of their varying impact on the study.5,22 Thus, our 
study, with 16 chronic conditions including CKD of a proven 
impact on mortality,24 reported an important effect on death. 
Marengoni et al23 in a study consisting of 22 conditions, 
including arthritis, polymyalgia, or rheumatoid arthritis of a 
proven impact on disability as well as Wong et al,25 including 
different psychiatric disorders, reported an association with 
disability and health-related quality, respectively, rather than 
on mortality. A third explanation for these differences may be 
the severity of the disease.8 Thereby, Gené et al26 described 
among community-dwelling patients of an age similar to 
our group, a mortality rate was 28.9% at the first year with 
a global comorbidity index of 2.1, whereas the mortality rate 
of our sample was 4.9% at the first year and the comorbidity 
index was 1.4. Interestingly, it should be noted that in this 
study, the effect of multimorbidity on mortality persisted after 
adjusting for functionality, unlike other studies.7,27 Probably, 
our results, which include ADL, support that disability in 
basic ADL was a less-sensitive predictor of functional decline 
than instrumental activities28 – as it was utilized in the studies 
by Marengoni et al and Wong et al.23,25 Furthermore, the effect 
of disability could modulate the effect of multimorbidity on 
mortality when the long disease states produce a period of 
disability along with other conditions, such as loneliness, 
Table 1 Baseline characteristics of the participants according to gender
Characteristics All, N=328 Men, N=126 Women, N=202 P-value
Marital status: married 134 (40.9%) 90 (71.4%) 44 (21.8%) ,0.001
Caregiver 174 (53.0%) 69 (54.8%) 105 (52.0%) 0.706
hypertension 249 (75.9%) 90 (71.4%) 159 (78.7%) 0.171
Dyslipidemia 168 (51.2%) 60 (47.6%) 108 (53.5%) 0.359
Diabetes mellitus 56 (17.1%) 21 (16.7%) 35 (17.3%) 0.997
Ischemic cardiomyopathy 20 (6.10%) 8 (6.35%) 12 (5.94%) 1.000
stroke 49 (14.9%) 24 (19.0%) 25 (12.4%) 0.136
Peripheral arterial disease 16 (4.88%) 8 (6.35%) 8 (3.96%) 0.476
Chronic pulmonary disease 34 (10.4%) 20 (15.9%) 14 (6.93%) 0.016
Dementia 31 (9.45%) 9 (7.14%) 22 (10.9%) 0.350
Parkinson’s disease 13 (3.96%) 8 (6.35%) 5 (2.48%) 0.089
heart failure 42 (12.8%) 16 (12.7%) 26 (12.9%) 1.000
Atrial fibrillation 41 (12.5%) 18 (14.3%) 23 (11.4%) 0.548
Anemia 56 (17.1%) 15 (11.9%) 41 (20.3%) 0.070
Chronic kidney disease 131 (40.8%) 49 (39.5%) 82 (41.6%) 0.797
Malignancy 42 (12.8%) 28 (22.2%) 14 (6.93%) ,0.001
Visual impairment 279 (85.1%) 113 (89.7%) 166 (82.2%) 0.090
Barthel index ,90 100 (30.5%) 30 (23.8%) 70 (34.7%) 0.051
Mini-mental examination ,24 90 (27.4%) 26 (20.6%) 64 (31.7%) 0.040
Charlson index, medium (Quartile 1; Quartile 3) 1 (0; 2) 1.5 (0; 3) 1 (0; 2) 0.002
Falls 0.4 (0.3–0.5) 0.2 (0.2–0.3) 0.5 (0.4–0.7) 0.006
Mini nutritional assessment 25 (10; 30) 24.5 (10; 30) 26 (14; 30) 0.016
No of comorbidities, medium (Quartile 1; Quartile 3) 4 (3; 5) 4 (3; 5) 4 (3; 5) 0.293
Comorbidities
0 0.921
1 16 (4.9%) 6 (4.8%) 10 (4.9%)
2 36 (11.0%) 12 (9.5%) 24 (11.9%)
3 70 (21.3%) 28 (22.2%) 42 (20.8%)
4+ 206 (62.8%) 80 (63.5%) 126 (62.4%)
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Figure 1 Kaplan–Meier curves for the most associated individual morbidities and combinations of morbidities with all-cause mortality by 3-year follow-up (A), and 5-year 
follow-up (B). Chi-square from the log-rank test is shown.
Abbreviations: CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; HTA, hypertension.
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dependence on a caregiver, and difficulties of access to the 
care system before death, which were not reflected in the 
analyses and would influence the main outcome.
Although little is known about the effect of multimorbid-
ity as specific combinations,6 this study found a mortality risk 
of 4.2 in a specific combination of three diseases at 3 years 
and, in turn, a mortality risk of 3.2 at the 5-year follow-up, 
among the oldest old. Similarly, other groups, such as the 
Incalzi et al29 community study in people aged 78 years and 
the Christakis and Escarce30 study among 76-year-old criti-
cally ill patients, reported a consistent multimorbidity effect 
on mortality. Furthermore, in this study, AF was the most 
common arrhythmia in the elderly with a 2.4 global mortality 
risk, and although CKD by itself was not significant as an 
individual predictor, in co-occurrence, with AF the mortality 
risk increased to 3.8. This is important because, due to shared 
Table 4 Interaction analysis between the most associated 
combination of two comorbidities models with death
Morbidities HR (95% CI)a P-value*
3-year follow-up
A)
Atrial fibrillation and CKD 4.28 (2.2; 8.3) 0.12
Atrial fibrillation 2.56 (1.4; 4.6)
CKD 1.54 (0.9; 2.6)
B)
Atrial fibrillation and  
visual impairment
2.74 (1.5; 4.9) 1.000
Atrial fibrillation 2.56 (1.4; 4.6)
Visual impairment 0.95 (0.5; 1.9)
C)
Anemia and CKD 3.14 (1.6; 6.2) 0.14
Anemia 1.69 (0.9; 3.0)
CKD 1.54 (0.9; 2.6)
5-year follow-up
A)
CKD and malignancy 2.72 (1.6; 4.5) 0.15
CKD 1.33 (0.96; 1.6)
Malignancy 1.81 (1.2; 2.7)
B)
Dyslipidemia and malignancy 2.79 (1.7; 4.7) 0.005
Dyslipidemia 0.83 (0.6; 1.2)
Malignancy 1.81 (1.2; 2.7)
C)
Anemia and malignancy 3.02 (1.6; 5.6) 0.061
Anemia 1.23 (0.8; 1.9)
Malignancy 1.81 (1.2; 2.7)
Notes: hr (95% CI) of time to death for combination of diseases model and 
independently adjusted diseases are shown. The P-value of a model including both 
diseases and the interaction term is also shown. aEach HR is for a specific (nonadjusted) 
model. *P-value of the interaction parameter for the two adjusted diseases, including 
the interaction between them, model.
Abbreviations: CI, confidence interval; CKD, chronic kidney disease; 
HR, hazard ratio.
Table 2 Unadjusted and adjusted Cox proportional hazard models of time to death for the most associated individual morbidities and 
multimorbidity combinations at 3-year follow-up
3-year follow-up Model 1 Model 2a Model 3b
One disease
Atrial fibrillation 2.51 (1.4; 4.6) 2.51 (1.4; 4.5) 2.41 (1.3; 4.3)
COPD 2.61 (1.4; 4.9) 2.41 (1.3; 4.6) 2.47 (1.3; 4.7)
Malignancy 1.81 (1.0; 3.4) 1.58 (0.8; 3.0) 1.9 (1.0; 3.6)
Two diseases
Atrial fibrillation and CKD 4.28 (2.2; 8.3) 4.59 (2.4; 8.9) 3.81 (1.9; 7.4)
Atrial fibrillation and visual impairment 2.74 (1.5; 4.9) 2.64 (1.5; 4.8) 2.66 (1.5; 4.8)
Anemia and CKD 3.14 (1.6; 6.2) 3.52 (1.8; 7.0) 2.40 (1.2; 4.9)
Three diseases
Atrial fibrillation, CKD, and visual impairment 4.58 (2.4; 8.9) 4.84 (2.5; 9.4) 4.19 (2.2; 8.2)
Anemia, CKD, and visual impairment 3.52 (1.8; 7.0) 4.08 (2.0; 8.2) 2.77 (1.4; 5.7)
Hypertension, atrial fibrillation, and visual impairment 2.54 (1.3; 4.9) 2.54 (1.3; 4.9) 2.51 (1.3; 4.8)
Notes: Hazard ratio (95% confidence interval) is shown. aAdjusted by gender; badjusted by Barthel index ,90.
Abbreviations: CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease.
Table 3 Unadjusted and adjusted Cox proportional hazard 
models of time to death for the most associated individual 
morbidities and multimorbidity combinations at 5-year follow-up
5-year follow-up Model 1 Model 2a Model 3b
One disease
Dementia 2.28 (1.5; 3.5) 2.41 (1.6; 3.7) 2.04 (1.3; 3.2)
Malignancy 1.81 (1.2; 2.7) 1.61 (1.0; 2.5) 1.84 (1.2; 2.8)
COPD 1.84 (1.2; 3.0) 1.74 (1.1; 2.8) 1.77 (1.1; 2.8)
Two diseases
CKD and malignancy 2.72 (1.6; 4.5) 2.46 (1.5; 4.1) 2.73 (1.6; 4.5)
Dyslipidemia and  
malignancy
2.79 (1.7; 4.7) 2.39 (1.4; 4.1) 2.83 (1.7; 4.8)
Anemia and malignancy 3.02 (1.6; 5.6) 2.94 (1.6; 5.6) 2.66 (1.4; 5.0)
Three diseases
Dyslipidemia,  
malignancy, and visual
2.9 (1.7; 4.9) 2.43 (1.4; 4.2) 2.91 (1.7; 5.0)
CKD, malignancy,  
and visual
2.74 (1.6; 4.6) 2.50 (1.5; 4.2) 2.82 (1.7; 4.8)
Hypertension,  
CKD, and malignancy
2.99 (1.7; 5.3) 2.63 (1.5; 4.7) 3.24 (1.8; 5.8)
Notes: Hazard ratio (95% confidence interval) is shown. aAdjusted by gender; 
badjusted by Barthel index ,90.
Abbreviations: CKD, chronic kidney disease; COPD, chronic obstructive 
pulmonary disease.
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atherosclerotic-structural vascular disease,31 these two condi-
tions impose a significant burden upon health in this group 
of octogenarians. Moreover, in turn, visual impairment was 
found as another important mortality predictor with a rate of 
risk of 4.2, when co-occurring with these conditions, probably 
as a result of multiple associated geriatric conditions. It should 
be suggested that in the elderly, an extended assessment of 
multimorbidity including sensorial capacities is needed.32 In 
addition, in this group of octogenarians, anemia, described 
as a predictor of mortality in the oldest old,33 showed a mor-
tality risk of 2.8 in combination with the earlier conditions. 
Therefore, this finding and the described association between 
anemia and left-ventricular hypertrophy or progressive loss of 
kidney function seem to reinforce the idea that anemia could 
act as a mortality multiplier, especially in patients with CKD, 
cardiovascular disease, and those with both.34
Regarding the follow-up at 5 years of the cohort, this study 
revealed that the co-occurrence of specific pairs of diseases in 
the same individual has an important multiplying or dampen-
ing effect on the mortality outcome. Therefore, in our group, 
the individual disease of cancer has a mortality risk of 1.8. 
In co-occurrence of cancer with CKD and hypertension, this 
combination led to a mortality risk of 3.2, which, in turn, is 
higher than the individual disease expected risk. Similarly, 
in the study by Newschaffer et al35 for women affected with 
breast cancer, the effect of comorbidity and cancer showed a 
higher mortality rate than expected. However, dementia and 
COPD have an individual described mortality risk of 2.0 and 
1.8, respectively, and yet in the subsequent analysis they do 
not appear in any significant multimorbidity combination, 
which shows a dampening effect on mortality. For all of the 
above, this study highlights that, although there has been a 
downward trend in cancer death rates in elderly people over 
the last two decades,36 if malignancy co-occurred with other 
specific diseases in the oldest old subjects, it might to be 
to targeted, especially because of its synergistic effect on 
mortality. Furthermore, at 3 years of cardiovascular diseases 
represented by combinations including AF appeared as one 
of the most important causes of death, despite at 5 years of 
malignancy and metabolic diseases, such as anemia and CKD, 
were the most important causes. Further population-based 
studies of the elderly are required to corroborate these find-
ings. Finally, the association of the pattern of cardiovascular 
risk factors, such as hypertension and dyslipidemia, with 
mortality in this group of very old patients was not surpris-
ing, due to their effect as a primary reason for the overall 
cardiovascular death rates for heart disease and stroke.37,38 
Therefore, the notion of a complex cumulative effect of 
health problems remains critical to the care of many people, 
and the development of more appropriate guidelines for use 
in multimorbid persons is required in order to better target 
interventions,39 especially in elderly patients.
The main strength of the Octabaix study is the use of a 
community-based sample of the same age group. This sample 
provides a representative range of the socioeconomic char-
acteristics of older residents in our area, all of whom were 
registered with a general practitioner and benefitted from a 
full range of health facilities. However, this strength might 
also constitute a weakness, since it limits the generalizability 
of its findings to other populations. Indeed, this study does 
have several limitations that should be acknowledged. First, 
our observational cohort study design can provide evidence 
of predictive association but not of cause of mortality. 
Another limitation is that we only assessed the occurrence 
of disease without taking into account its severity or stage, 
suggesting that further studies should be implemented.
Conclusion
In conclusion, multimorbidity, as specific combinations, 
is associated with mortality in the oldest old. The multi-
morbidity pattern of AF, CKD, and visual impairment at 
3-year follow-up and the pattern of hypertension, CKD, and 
malignancy at 5-year follow-up are the strongest predictors of 
mortality for all causes. Furthermore, cancer has a synergistic 
effect on mortality and may lead specific disease combina-
tions to have more than an additive risk on the effect of 
death. These findings contribute to better understanding the 
needed multimorbidity approach in clinical practice rather 
than the individual diseases approach, as well as to design 
future studies of multimorbidity patterns rather than the total 
account of morbidities, in order to reduce mortality rates of 
very elderly people, a group that lacks information.
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